From the 2020 Joint Annual Meeting (June 30, 2020)
Presented by Janelle Chiasera, PhD
According to the third universal definition of myocardial infarction, detection of cardiac troponins (cTnI or cTnT) are the preferred markers for the diagnosis of acute myocardial infarction (AMI). The FDA recently approved a fifth generation assay capable of detecting troponin at levels 10- to 100-fold lower than levels measured by contemporary troponin assays. This marked increment in sensitivity has the potential to significantly alter our current approach to the diagnosis of AMI. Join this session as we take a deep dive into troponins from history to high sensitivity.
At the conclusion of this presentation, participants will be able to:
- Describe the basic biology of troponin and its use in muscle contraction
- Summarize the criteria for diagnosing acute myocardial infarction using the AHAs third Universal definition
- Differentiate between the fourth generation and fifth generation troponin assays including pro and cons
This recorded presentation is P.A.C.E. ® accredited. The instruction level for this activity is Intermediate. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the area of Chemistry will be awarded to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT Board of Certification and all states, including Florida and California, as an approved provider of continuing education for recertification and licensure. ASCLS is an approved provider with CE Broker for Florida licensees.
LEVEL OF INSTRUCTION
This intermediate-level program is appropriate for laboratory professionals working in clinical, public health and academic settings.